.: "targeted cgrp small molecule antagonists for acute migraine therapy."...: "evidence for decreased calcitonin gene-related peptide (cgrp) receptors and compromised responsiveness to cgrp of fetoplacental vessels in preeclamptic pregnancies.".
....
.
schneider said that he is "not aware of any relevant risk of the drug" and that his team has "not observed side effects in thousands of treated animals.".
.
.
.